Management of Spironolactone in Heart Failure with Reduced eGFR

Introduction to Spironolactone Management

• The American College of Cardiology recommends continuing spironolactone at a reduced dose of 12.5 mg once daily or every other day, with close monitoring of potassium and renal function, as the mortality benefit persists even in advanced chronic kidney disease despite increased risk of adverse events 1

Rationale for Continuation

• Spironolactone discontinuation is associated with a 2-4 fold higher risk of subsequent adverse cardiovascular events, even when stopped for hyperkalemia or renal dysfunction, according to the European Society of Cardiology 2, 3

Dosing and Monitoring

• The American College of Cardiology provides dosing recommendations for spironolactone in patients with eGFR 30-49 mL/min/1.73 m², recommending an initial dose of 12.5 mg once daily or every other day, with maintenance dosing of 12.5-25 mg once daily 1
• If potassium level is ≤5.0 mEq/L, reduce spironolactone to 12.5 mg once daily, as recommended by the European Journal of Heart Failure 1
• If potassium level is 5.0-5.5 mEq/L, reduce spironolactone to 12.5 mg every other day, as recommended by the European Journal of Heart Failure 4, 5, 6

Intensive Monitoring Protocol

• Check potassium and creatinine at 1 week after dose adjustment, and recheck at 4 weeks, as recommended by the European Journal of Heart Failure 1, 4, 5, 6
• Check potassium and creatinine at 8 weeks and 12 weeks, as recommended by the European Journal of Heart Failure 4, 5, 6

Critical Thresholds for Discontinuation

• Hold spironolactone if creatinine rises to >220 μmol/L (2.5 mg/dL), and reduce to 12.5 mg every other day, as recommended by the European Journal of Heart Failure 4
• Permanently discontinue spironolactone if recurrent hyperkalemia >6.0 mEq/L despite dose reduction and elimination of other contributing factors, as recommended by the European Journal of Heart Failure 3

Common Pitfalls to Avoid

• Do not automatically discontinue spironolactone based on eGFR alone, as emphasized by the 2025 ESC consensus statement, which recommends continuing spironolactone whenever possible 2, 3
• Do not ignore concurrent volume depletion, as high-dose loop diuretics combined with spironolactone can cause hypovolemia and pre-renal azotemia, which may be reversible with volume optimization rather than spironolactone discontinuation, as recommended by the European Journal of Heart Failure 2